Notes from SAPA-NC 2026 — Beyond Borders, Beyond Biotech Frontiers

Last week at the SAPA-NC Biotech Innovation & Investment Summit in Research Triangle Park, one of the most thought-provoking talks centered on a first-in-class dual HIF-1/2 inhibitor (S9N) for cancer therapy. The speaker walked us through how HIF-1α is required for development of the circulatory system — heart, blood vessels, yolk sac, and blood itself — and how blocking HIF-1/2 in tumors achieved complete responses in cancer models that had previously resisted immune checkpoint blockade (44% CR rate vs. 4% with ICB alone, across 5 tumor models).

It was a powerful reminder that one of biology’s most elegant control circuits — the HIF–EPO axis — sits at the heart of so much modern oncology, hematology, and stem cell research.

The Oxygen Sensor Behind EPO

Erythropoietin (EPO) is the body’s master regulator of red blood cell production, and its expression is governed almost entirely by HIF (hypoxia-inducible factor). When oxygen levels drop, HIF-1α and HIF-2α stabilize, translocate to the nucleus, and switch on the EPO gene. Higher EPO → more erythropoiesis → more oxygen-carrying capacity.

This is the very pathway whose discovery earned the 2019 Nobel Prize in Physiology or Medicine, and it remains one of the most actively studied signaling cascades in biology today.

Why This Matters for the Bench Scientist

If you’re working on:

- Hypoxia signaling — EPO is the canonical HIF target gene

- Erythropoiesis & hematopoiesis — EPO drives the proliferation and terminal differentiation of CFU-E and other erythroid progenitors

- Neuroprotection in hypoxia — non-erythropoietic EPO signaling protects neurons against ischemic injury

- Cancer biology — tumor microenvironments are hypoxic, and EPO/EPOR signaling in this context is being actively re-examined

- Cardiovascular development — as the SAPA-NC talk reminded us, the same HIF axis governs vascular and erythroid development

…you need a reliable, bioactive EPO protein in your toolkit.

Biofargo Recombinant Human EPO Protein

At Biofargo, we offer HEK293-derived recombinant human EPO designed for research applications.

Whether you’re studying the HIF-EPO axis, modeling erythropoiesis from CFU-E progenitors, or exploring tissue-protective signaling in hypoxia, our EPO protein is verified for bioactivity on every lot.